A growing momentum for earlier treatment of psoriasis has the potential to improve outcomes with oral therapies and biologics ...

The psoriasis pipeline possesses some drugs in mid- and late-stage development to be approved in the near future. The emerging landscape holds a dive ...

Posters presented at the 2025 American Academy of Dermatology Annual Meeting found tildrakizumab outcomes to have a mean drug ...

Arcutis Biotherapeutics' Zoryve drives revenue growth and nears cash flow positivity, yet high valuation warrants a Hold ...

Discover the early warning signs of psoriatic arthritis that could prevent permanent joint damage, plus expert advice on treatment options and daily management.

Manifestations may range from being mild to severe. There are four variants of which the most common is the chronic plaque psoriasis. These lesions are typically seen on the scalp, face, buttocks, ...

Mild side effects can occur with Otezla ... plaque psoriasis can cause hair loss if the condition affects your scalp. (Otezla is used to treat plaque psoriasis. If you notice hair loss during ...

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that David Topper, ...

INDICATIONS ZORYVE cream, 0.3%, is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older. ZORYVE cream, 0.15%, ...